Search Results - "Yoshiyasu Umeda"

Systemic capillary leak syndrome triggered by anti‐programmed death 1 checkpoint inhibitor in psoriasis by Umeda, Yoshiyasu, Hayashi, Hiroaki, Sugiyama, Seiko, Aoyama, Yumi

“…Programmed death 1 (PD‐1) inhibitors are increasingly used for the treatment of malignancies. Despite the clinical benefits, unpredictable and potentially…”
Get full text

Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients by Nakamura, Yasuhiro, Namikawa, Kenjiro, Kiniwa, Yukiko, Kato, Hiroshi, Yamasaki, Osamu, Yoshikawa, Shusuke, Maekawa, Takeo, Matsushita, Shigeto, Takenouchi, Tatsuya, Inozume, Takashi, Nakai, Yasuo, Fukushima, Satoshi, Saito, Shintaro, Otsuka, Atsushi, Fujimoto, Noriki, Isei, Taiki, Baba, Natsuki, Matsuya, Taisuke, Tanaka, Ryo, Kaneko, Takahide, Onishi, Masazumi, Kuwatsuka, Yutaka, Nagase, Kotaro, Onuma, Takehiro, Nomura, Motoo, Umeda, Yoshiyasu, Yamazaki, Naoya

“…Although anti-PD-1 antibody monotherapy (PD-1) is commonly used to treat advanced acral melanoma (AM), its efficacy is limited. Further, data on the efficacy…”
Get full text

Long‐term resolution of invasive extramammary Paget’s disease with multiple regional lymph node metastases solely with regional lymph node dissection by Kawahara, Yu, Umeda, Yoshiyasu, Yamaguchi, Buntaro, Kamimura, Anna, Teramoto, Yukiko, Nakamura, Yasuhiro

Get full text

TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment by Kawashima, Shusuke, Inozume, Takashi, Kawazu, Masahito, Ueno, Toshihide, Nagasaki, Joji, Tanji, Etsuko, Honobe, Akiko, Ohnuma, Takehiro, Kawamura, Tatsuyoshi, Umeda, Yoshiyasu, Nakamura, Yasuhiro, Kawasaki, Tomonori, Kiniwa, Yukiko, Yamasaki, Osamu, Fukushima, Satoshi, Ikehara, Yuzuru, Mano, Hiroyuki, Suzuki, Yutaka, Nishikawa, Hiroyoshi, Matsue, Hiroyuki, Togashi, Yosuke

“…BackgroundPatients with cancer benefit from treatment with immune checkpoint inhibitors (ICIs), and those with an inflamed tumor microenvironment (TME) and/or…”
Get full text

Comparison of surgical morbidities between LigaSure™ and conventional techniques in inguinal or ilioinguinal lymph node dissection for skin cancer: A single center retrospective study by Umeda, Yoshiyasu, Teramoto, Yukiko, Asami, Yuri, Matsuya, Taisuke, Saito, Shintaro, Sasaki, Katsuhito, Baba, Natsuki, Ishizuki, Shoichiro, Kamimura, Anna, Yamaguchi, Buntaro, Kawahara, Yu, Takai, Sayaka, Izumi, Teruaki, Doi, Reiichi, Mori, Tatsuhiko, Nakamura, Yasuhiro

“…Skin cancer patients with clinical nodal disease or whose positive sentinel nodes had great tumor burden remain candidates for regional lymph node dissections…”
Get full text

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study by Umeda, Yoshiyasu, Yoshikawa, Shusuke, Kiniwa, Yukiko, Maekawa, Takeo, Yamasaki, Osamu, Isei, Taiki, Matsushita, Shigeto, Nomura, Motoo, Nakai, Yasuo, Fukushima, Satoshi, Saito, Shintaro, Takenouchi, Tatsuya, Tanaka, Ryo, Kato, Hiroshi, Otsuka, Atsushi, Matsuya, Taisuke, Baba, Natsuki, Nagase, Kotaro, Inozume, Takashi, Onuma, Takehiro, Kuwatsuka, Yutaka, Fujimoto, Noriki, Kaneko, Takahide, Onishi, Masazumi, Namikawa, Kenjiro, Yamazaki, Naoya, Nakamura, Yasuhiro

“…Immune checkpoint inhibitors (ICIs) have a lower efficacy in mucosal melanoma (MUM) than in cutaneous melanoma. The use of combination treatments with…”
Get full text

CD106 in tumor-specific exhausted CD8+ T cells mediates immunosuppression by inhibiting TCR signaling by Naoi, Yuto, Morinaga, Takao, Nagasaki, Joji, Ariyasu, Ryo, Ueda, Youki, Yamashita, Kazuo, Zhou, Wenhao, Kawashima, Shusuke, Kawase, Katsushige, Honobe-Tabuchi, Akiko, Ohnuma, Takehiro, Kawamura, Tatsuyoshi, Umeda, Yoshiyasu, Kawahara, Yu, Nakamura, Yasuhiro, Kiniwa, Yukiko, Yamasaki, Osamu, Fukushima, Satoshi, Kawazu, Masahito, Suzuki, Yutaka, Nishikawa, Hiroyoshi, Hanazawa, Toyoyuki, Ando, Mizuo, Inozume, Takashi, Togashi, Yosuke

“…T cell exhaustion is a major contributor to immunosuppression in the tumor microenvironment (TME). Blockade of key regulators of T cell exhaustion, such as…”
Get full text

Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study by Bai, Xue, Lawless, Aleigha R., Czapla, Juliane A., Gerstberger, Stefanie C., Park, Benjamin C., Jung, Seungyeon, Johnson, Rebecca, Yamazaki, Naoya, Ogata, Dai, Umeda, Yoshiyasu, Li, Caili, Guo, Jun, Flaherty, Keith T., Nakamura, Yasuhiro, Namikawa, Kenjiro, Long, Georgina V., Menzies, Alexander M., Johnson, Douglas B., Sullivan, Ryan J., Boland, Genevieve M., Si, Lu

“…Anti-Program-Death-1 (PD-1) is a standard adjuvant therapy for patients with resected melanoma. We hypothesized that there are discrepancies in survival,…”
Get full text

Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J‐BASE‐MARGIN) by Kamimura, Anna, Nakamura, Yasuhiro, Takenouchi, Tatsuya, Matsushita, Shigeto, Omodaka, Toshikazu, Yamamura, Kentaro, Uchi, Hiroshi, Yoshikawa, Shusuke, Yanagisawa, Hiroto, Ito, Takamichi, Kiyohara, Yoshio, Nakamura, Yoshio, Aoki, Megumi, Ishizuki, Shoichiro, Oashi, Kohei, Miyagawa, Takuya, Maeda, Taku, Ogata, Dai, Hatta, Naohito, Ohe, Shuichi, Isei, Taiki, Takahashi, Akira, Umeda, Yoshiyasu, Yamaguchi, Buntaro, Ishikawa, Masashi, Horimoto, Kohei, Fujsawa, Yasuhiro, Uehara, Jiro, Shibayama, Yoshitsugu, Kiniwa, Yukiko, Kawahara, Yu, Matsuya, Taisuke, Uhara, Hisashi, Kato, Junji, Nakamura, Yoshiyuki, Murakami, Takuo, Namikawa, Kenjiro, Yoshino, Koji, Funakoshi, Takeru, Takatsuka, Sumiko, Matsui, Yu, Sasaki, Jin, Koga, Hiroshi, Yokota, Kenji, Komori, Takaya, Fukushima, Satoshi, Yamazaki, Naoya

“…Basal cell carcinoma is the most common type of skin cancer, and surgical excision with clear margins is the standard of care. Surgical margins are determined…”
Get full text

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study by Bai, Xue, Shaheen, Ahmed, Grieco, Charlotte, d’Arienzo, Paolo D., Mina, Florentia, Czapla, Juliane A., Lawless, Aleigha R., Bongiovanni, Eleonora, Santaniello, Umberto, Zappi, Helena, Dulak, Dominika, Williamson, Andrew, Lee, Rebecca, Gupta, Avinash, Li, Caili, Si, Lu, Ubaldi, Martina, Yamazaki, Naoya, Ogata, Dai, Johnson, Rebecca, Park, Benjamin C., Jung, Seungyeon, Madonna, Gabriele, Hochherz, Juliane, Umeda, Yoshiyasu, Nakamura, Yasuhiro, Gebhardt, Christoffer, Festino, Lucia, Capone, Mariaelena, Ascierto, Paolo Antonio, Johnson, Douglas B., Lo, Serigne N., Long, Georgina V., Menzies, Alexander M., Namikawa, Kenjiro, Mandala, Mario, Guo, Jun, Lorigan, Paul, Najjar, Yana G., Haydon, Andrew, Quaglino, Pietro, Boland, Genevieve M., Sullivan, Ryan J., Furness, Andrew J.S., Plummer, Ruth, Flaherty, Keith T.

“…Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma…”
Get full text

Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration by Morinaga, Takao, Inozume, Takashi, Kawazu, Masahito, Ueda, Youki, Sax, Nicolas, Yamashita, Kazuo, Kawashima, Shusuke, Nagasaki, Joji, Ueno, Toshihide, Lin, Jason, Ohara, Yuuki, Kuwata, Takeshi, Yukami, Hiroki, Kawazoe, Akihito, Shitara, Kohei, Honobe-Tabuchi, Akiko, Ohnuma, Takehiro, Kawamura, Tatsuyoshi, Umeda, Yoshiyasu, Kawahara, Yu, Nakamura, Yasuhiro, Kiniwa, Yukiko, Morita, Ayako, Ichihara, Eiki, Kiura, Katsuyuki, Enokida, Tomohiro, Tahara, Makoto, Hasegawa, Yoshinori, Mano, Hiroyuki, Suzuki, Yutaka, Nishikawa, Hiroyoshi, Togashi, Yosuke

“…Some patients experience mixed response to immunotherapy, whose biological mechanisms and clinical impact have been obscure. We obtained two tumor samples from…”
Get full text

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyResearch in context by Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, Keith T. Flaherty

“…Background: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant…”
Get full text

Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyCapsule Summary by Xue Bai, MD, Aleigha R. Lawless, BS, Juliane A. Czapla, MS, Stefanie C. Gerstberger, MD, PhD, Benjamin C. Park, MD, Seungyeon Jung, BA, Rebecca Johnson, MN, Naoya Yamazaki, MD, PhD, Dai Ogata, MD, PhD, Yoshiyasu Umeda, MD, Caili Li, MB, Jun Guo, MD, PhD, Keith T. Flaherty, MD, Yasuhiro Nakamura, MD, PhD, Kenjiro Namikawa, MD, PhD, Georgina V. Long, MBBS, PhD, Alexander M. Menzies, MBBS, PhD, Douglas B. Johnson, MD, Ryan J. Sullivan, MD, Genevieve M. Boland, MD, PhD, Lu Si, MD

“…Background: Anti-Program-Death-1 (PD-1) is a standard adjuvant therapy for patients with resected melanoma. We hypothesized that there are discrepancies in…”
Get full text

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study by Bai, Xue, Shaheen, Ahmed, Grieco, Charlotte, d’Arienzo, Paolo D., Mina, Florentia, Czapla, Juliane A., Lawless, Aleigha R., Bongiovanni, Eleonora, Santaniello, Umberto, Zappi, Helena, Dulak, Dominika, Williamson, Andrew, Lee, Rebecca, Gupta, Avinash, Li, Caili, Si, Lu, Ubaldi, Martina, Yamazaki, Naoya, Ogata, Dai, Johnson, Rebecca, Park, Benjamin C., Jung, Seungyeon, Madonna, Gabriele, Hochherz, Juliane, Umeda, Yoshiyasu, Nakamura, Yasuhiro, Gebhardt, Christoffer, Festino, Lucia, Capone, Mariaelena, Ascierto, Paolo Antonio, Johnson, Douglas B., Lo, Serigne N., Long, Georgina V., Menzies, Alexander M., Namikawa, Kenjiro, Mandala, Mario, Guo, Jun, Lorigan, Paul, Najjar, Yana G., Haydon, Andrew, Quaglino, Pietro, Boland, Genevieve M., Sullivan, Ryan J., Furness, Andrew J.S., Plummer, Ruth, Flaherty, Keith T.

Get full text